Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapy experienced more pronounced vertex hair loss and were less responsive to minoxidil treatment compared to those on endocrine monotherapy.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.